Healthy Subjects Clinical Trial
Primary:
To assess the effects of CYP2B6 inhibition by repeated dose Clopidogrel (75 mg/day)
co-administration on the single-dose pharmacokinetics of Neramexane
Secondary:
To assess safety and tolerability of Neramexane single dose treatment alone and
co-administration of a Neramexane single-dose with a Clopidogrel repeated dose treatment
Status | Completed |
Enrollment | 0 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Healthy adult subject of white origin, who is able to read, to write and fully understand German language 2. Aged 18 to 45 years 3. BMI of 18-28 kg/m2 and a body weight of 50-90 kg 4. Willing and able to provide written informed consent after having been informed of the requirements and the restrictions of the study. Female subjects of childbearing potential must agree to use a highly effective method of birth control defined as those which result in a low failure rate (i.e. less than 1 % per year) when used consistently and correctly such as sexual abstinence, vasectomised partner, non hormonal IUDs, double barrier methods, for instance, e.g. condom and spermicide cream. Exclusion Criteria: 1. History of clinically relevant allergy or known hypersensitivity to Neramexane/ Memantine/Amantadine and their derivatives 2. History of clinically relevant allergy or known hypersensitivity to Clopidogrel 3. Exposure to another investigational agent within the last two months before Day 1 of Period 1 4. History of clinically relevant allergy or known hypersensitivity to any inactive ingredient in any of the used investigational products or the metabolic inhibitor 5. Lactating or pregnant females or females planning to become pregnant during study conduct or within 2 months after end of study 6. Any contraindications which are indicated in the topically valid SPC for Plavix®: severe hepatic impairment; active pathological bleeding such as peptic ulcer or intracranial hemorrhage Lack of suitability for the trial: 7. Any evidence of a significant cardiovascular, pulmonary, renal, hepatic, gastrointestinal, endocrinological, metabolic or other disease at screening 8. History of malignancy 9. Any clinically relevant deviation in clinical or laboratory assessment 10. ECG abnormalities of clinical relevance, in particular abnormal prolongations of QT/QTc-interval (i.e. QTc = 450 ms, PQ = 220 ms) 11. Systolic blood pressure <95 mmHg or >150 mmHg or diastolic blood pressure < 50 mmHg or >90 mmHg in supine position 12. Pulse rate <45 or >100 beats per minute 13. Chronic or acute clinically relevant infections 14. Acute or chronic disease, especially psychiatric or neurologic disorders 15. History of alcohol or drug dependence 16. Alcohol consumption averaging more than 40 g for male and more than 20 g for female subjects daily within the last year 17. Regular caffeine consumption averaging more than 1 L of coffee and/or tea daily or more than 1 L of caffeine-containing lemonades per day within the last year 18. Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal products (e.g. cholecystectomy, ulcus, etc.) 19. Anticipated donation of spermatocytes or oocytes for medically assisted reproduction techniques [ART] within two months after the last dose of the present study 20. Use of any prescribed medication for four weeks prior to the first administration of IMP. - Regular use of over-the-counter drugs in the 4 weeks prior to the first administration of the IMP - Occasional use of OTC drugs (except paracetamol, maximum 1 g/day) within the 2 weeks prior to the first administration of the IMP. - Stable intake of thyroid hormone substitution will be allowed. 21. Use of any food, food supplement or medication known to induce or inhibit CYP3A4 or other cytochrome P450 enzymes within two weeks preceding the start of the study (Day 1), e.g. grapefruit, St. John's wort 22. Female subjects who employed any form of hormonal contraception within 2 months prior to study Day 1 (e.g. oral contraceptives, hormone releasing intrauterine contraceptive devices [IUDs], etc.) 23. Consumption of xanthine derivates (including caffeine) within two days prior to Day 1 24. Smoker and user of snuff, nicotine replacement and chewing tobacco 25. Previous enrolment into the clinical phase of the current study 26. Positive results in any of the serology tests 27. Blood donation more than 450 mL within 60 days prior to Day 1 28. Positive pregnancy test, if female 29. Positive drug screen or alcohol test |
Masking: Open Label
Country | Name | City | State |
---|---|---|---|
Germany | AAIPharma Deutschland gmbH & Co. KG | Neu Ulm | Bayern |
Lead Sponsor | Collaborator |
---|---|
Merz Pharmaceuticals GmbH |
Germany,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |